CN111875619B — 巴洛沙韦酯的晶型及其制备方法
Assigned to Nycrist Pharmatech Ltd · Expires 2021-06-25 · 5y expired
What this patent protects
本发明涉及一种巴洛沙韦酯的晶型及其制备方法,使用Cu‑Kα辐射,所述晶型的粉末X射线衍射图谱中,在衍射角2θ为5.1±0.2°,8.7±0.2°,15.2±0.2°,19.7±0.2°处具有特征峰;或,所述晶型的粉末X射线衍射图谱中,在衍射角2θ为5.1±0.2°,8.7±0.2°,12.4±0.2°,13.5±0.2°,15.2±0.2°,16.7±0.2°,18.4±0.2°,19.7±0.2°,22.2±0.2°,26.5±0.2°处具有特征峰。所述晶型的溶出速度较快,利于在人体胃肠道内的吸收,提高药物的生物利用度。
USPTO Abstract
本发明涉及一种巴洛沙韦酯的晶型及其制备方法,使用Cu‑Kα辐射,所述晶型的粉末X射线衍射图谱中,在衍射角2θ为5.1±0.2°,8.7±0.2°,15.2±0.2°,19.7±0.2°处具有特征峰;或,所述晶型的粉末X射线衍射图谱中,在衍射角2θ为5.1±0.2°,8.7±0.2°,12.4±0.2°,13.5±0.2°,15.2±0.2°,16.7±0.2°,18.4±0.2°,19.7±0.2°,22.2±0.2°,26.5±0.2°处具有特征峰。所述晶型的溶出速度较快,利于在人体胃肠道内的吸收,提高药物的生物利用度。
Drugs covered by this patent
- Xofluza (BALOXAVIR MARBOXIL) · Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.